SCHEMBL14933676

SCHEMBL14933676

O=[N+]([O-])c1ccc(Nc2cc(Cl)ccc2O)c2nonc12

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 12/20 0.70
▸ KMT2A Q03164 12/20 0.70
▸ GAA P10253 2/20 0.70
▸ POLB P06746 2/20 0.70
▸ L3MBTL1 Q9Y468 2/20 0.70
▸ MYC P01106 7/20 0.56
▸ IDO1 P14902 5/20 0.56
▸ MAX P61244 3/20 0.54
▸ PSMD14 O00487 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ RXFP1 Q9HBX9 1/20 0.54
▸ NPC1 O15118 2/20 0.49
▸ OPRD1 P41143 1/20 0.49
▸ OPRK1 P41145 1/20 0.49
▸ TLR9 Q9NR96 1/20 0.49
▸ RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14933668 0.85 TNF (0.66) MEN1KMT2AGAAPOLBL3MBTL1
SCHEMBL2464366 0.82 MEN1 (1.00) MEN1KMT2AGAAPOLBL3MBTL1
SCHEMBL3702011 0.81 IDO1 (0.76) MEN1KMT2AGAAPOLBL3MBTL1
SCHEMBL17927389 0.80 IDO1 (0.67) MEN1KMT2AGAAPOLBL3MBTL1
SCHEMBL31589561 0.79 MEN1 (0.71) MEN1KMT2AGAAPOLBL3MBTL1
SCHEMBL17927312 0.78 MEN1 (0.81) MEN1KMT2AGAAPOLBL3MBTL1
SCHEMBL6833705 0.77 MEN1 (0.58) MEN1KMT2AGAAPOLBL3MBTL1
SCHEMBL14933670 0.77 IDO1 (0.69) MEN1KMT2AGAAPOLBL3MBTL1
SCHEMBL17927315 0.76 MYC (0.73) MEN1KMT2AGAAPOLBL3MBTL1
SCHEMBL6836399 0.76 MEN1 (0.63) MEN1KMT2AGAAPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096554-B2 Drugs for inhibiting p38 and uses thereof Universidad Autónoma de Madrid (ES) 2015-08-04 — — US disclosed
US-9096554-B2 Drugs for inhibiting p38 and uses thereof Universidad Autónoma de Madrid (ES) 2015-08-04 — — US disclosed
US-9096554-B2 Drugs for inhibiting p38 and uses thereof Universidad Autónoma de Madrid (ES) 2015-08-04 — — US disclosed
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma de Madrid (ES) 2014-10-02 — — US disclosed
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma de Madrid (ES) 2014-10-02 — — US disclosed
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma de Madrid (ES) 2014-10-02 — — US disclosed
EP-2774613-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma De Madrid (ES) 2014-09-10 — — EP disclosed
EP-2774613-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma De Madrid (ES) 2014-09-10 — — EP disclosed
WO-2013064714-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma de Madrid (ES) 2013-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF MAPK1, MAPK4, MAPK8 MEN1 3940/4885KMT2A 3069/4885GAA 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback